Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Dermata Therapeutics, Inc.

Accession: 0001493152-26-025441

Filed: 2026-05-27

Period: 2026-05-27

CIK: 0001853816

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Submission of Matters to a Vote of Security Holders

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-10.1 (ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001853816

0001853816

2026-05-27

2026-05-27

0001853816

DRMA:CommonStockParValue0.0001PerShareMember

2026-05-27

2026-05-27

0001853816

DRMA:WarrantsExercisableForOneShareOfCommonStockMember

2026-05-27

2026-05-27

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): May 27, 2026

Dermata

Therapeutics, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-40739

86-3218736

(State

or Other Jurisdiction

of

Incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification

No.)

3525

Del Mar Heights Rd., #322

San

Diego, CA

92130

(Address

of principal executive offices)

(Zip

Code)

(858)

800-2543

(Registrant’s

telephone number, including area code)

N/A

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of Each Class:

Trading

Symbol

Name

of Each Exchange on which Registered

Common

Stock, par value $0.0001 per share

DRMA

The

Nasdaq Capital Market

Warrants,

exercisable for one share of Common Stock

DRMAW

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR§230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☒

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of

Certain Officers.

On

May 27, 2026, Dermata Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the

“Annual Meeting”). At the Annual Meeting, shareholders approved an amendment to the Company’s 2021 Omnibus

Equity Incentive Plan (the “2021 Plan”) to increase the number of shares available for issuance thereunder

to 402,214 shares (the “Plan Amendment”).

The

foregoing description of the Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full

text of the Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item

5.07 Submission of Matters to a Vote of Security Holders.

At

the Annual Meeting, 2,374,471 common

shares, or approximately 59% of

the outstanding shares of common stock entitled to vote, were represented by proxy or in person. The matters voted on at the Annual Meeting

were: (1) the election of three Class II directors; (2) the ratification of the appointment of CBIZ CPAs P.C.

as the Company’s independent registered public accounting

firm for the fiscal year ending December 31, 2026 (the “Auditor Proposal”); (3) the approval, for purposes

of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company’s common stock, par value $0.0001 per share

(“Common Stock”), underlying certain warrants issued by the Company pursuant to that certain Securities Purchase

Agreement, dated as of December 23, 2025, by and among the Company and the investors named on the signatory pages thereto, and the Engagement

Letter, as amended, between the Company and H.C. Wainwright & Co., LLC, dated as of September 10, 2024 (the “Engagement

Letter”), in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of

such warrants (the “Issuance Proposal”); (4) the approval of the repricing of warrants exercisable for up to

120,734 shares of Common Stock issued by the Company to investors pursuant to certain securities purchase agreements, each dated as of

January 21, 2025, and each as amended on December 23, 2025 (the “Warrant Repricing Proposal”); (5) the approval

of an amendment to the 2021 Plan to increase the maximum aggregate number of shares of Common Stock reserved for issuance under the 2021

Plan to 402,214 shares (the “Plan Amendment Proposal”); and (6) the approval of the adjournment of the Annual

Meeting to the extent there are insufficient votes at the Annual Meeting to approve the Issuance Proposal, the Repricing Proposal and/or

the Plan Amendment Proposal (the “Adjournment Proposal”). The final voting results were as follows:

1.

The stockholders elected David Hale, Steven Mento, Ph.D. and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting

and until their successors have been duly elected and qualified. The votes were cast for this matter as follows:

Nominee

For

Withheld

Broker

Non-Votes

David Hale

1,258,269

47,546

1,068,656

Steven Mento Ph.D.

1,258,871

46,944

1,068,656

Brittany Bradrick

1,262,134

43,681

1,068,656

2.

The Auditor Proposal was approved based upon the following votes:

For

Against

Abstain

2,329,537

43,122

1,812

3.

The Issuance Proposal was approved based upon the following votes:

For

Against

Abstain

Broker

Non-Votes

315,477

22,696

967,642

1,068,656

4.

The Warrant Repricing Proposal was approved based upon the following votes:

For

Against

Abstain

Broker

Non-Votes

439,573

21,203

845,039

1,068,656

5.

The Plan Amendment Proposal was approved based upon the following votes:

For

Against

Abstain

Broker

Non-Votes

1,243,540

47,441

14,834

1,068,656

6.

The Adjournment Proposal was approved based upon the following votes:

For

Against

Abstain

1,269,857

21,137

14,821

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

10.1

Fourth Amendment to the

Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan.

104

Cover Page Interactive Data File (embedded

within the Inline XBRL document).

Signature

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

DERMATA

THERAPEUTICS, INC.

Dated:

May 27, 2026

By:

/s/

Gerald T. Proehl

Gerald

T. Proehl

Chief

Executive Officer

EX-10.1

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit 10.1

FOURTH AMENDMENT TO THE

DERMATA THERAPEUTICS, INC.

2021 OMNIBUS EQUITY INCENTIVE

PLAN

This

Fourth Amendment (the “Amendment”) to the Dermata Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”)

of Dermata Therapeutics, Inc. (the “Company”), is made as of March 25, 2026. All capitalized terms used but not defined

in this Amendment shall have the meanings assigned to such terms in the Plan.

WITNESSETH:

WHEREAS,

Section 17.2 of the Plan reserves to the Board of Directors of the Company (the “Board”) the right to amend the Plan

from time to time;

WHEREAS,

the Board desires to increase the number of shares of Common Stock reserved for issuance under the Plan from 153,586 to 402,214 shares,

subject to approval by the Company’s stockholders.

NOW,

THEREFORE, be it effective as of the date of approval by the Company’s stockholders, the Plan is hereby amended as follows:

1. Amendment

to Section 4.1(a). Section 4.1(a) of the Plan is hereby amended and restated in its entirety, to read as follows:

(a) Subject

to adjustment pursuant to Section 4.3 and any other applicable provisions hereof, the maximum aggregate number of shares of Common Stock,

which may be issued under all Awards granted to Participants under the Plan, shall be 402,214 shares; all of which may, but need not,

be issued in respect of Incentive Stock Options.

2. This

Amendment shall be subject to approval by the stockholders of the Company within 12 months after the date this Amendment is adopted. Such

stockholder approval shall be obtained in the manner and to the degree required under applicable laws. Notwithstanding any provision in

the Plan to the contrary, exercise of any Option granted for shares of Common Stock in excess of those remaining available for grant under

the Plan in the absence of such Amendment before the Company has obtained stockholder approval of this Amendment in accordance with this

Section 2 shall be conditioned upon obtaining such stockholder approval of this Amendment in accordance with this Section 2.

3. Except

as set forth herein, the Plan shall remain in full force and effect without modification.

IN WITNESS WHEREOF, the undersigned officer hereby certifies that

the foregoing amendment to the Plan was duly adopted and approved by the Board.

DERMATA THERAPEUTICS, INC.

Dated:

March 25, 2026

By:

/s/

Gerald T. Proehl

Gerald

T. Proehl

Chief

Executive Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 27, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 27, 2026

Entity File Number

001-40739

Entity Registrant Name

Dermata

Therapeutics, Inc.

Entity Central Index Key

0001853816

Entity Tax Identification Number

86-3218736

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

3525

Del Mar Heights Rd.

Entity Address, Address Line Two

#322

Entity Address, City or Town

San

Diego

Entity Address, State or Province

CA

Entity Address, Postal Zip Code

92130

City Area Code

(858)

Local Phone Number

800-2543

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

true

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

DRMA

Security Exchange Name

NASDAQ

Warrants, exercisable for one share of Common Stock

Title of 12(b) Security

Warrants,

exercisable for one share of Common Stock

Trading Symbol

DRMAW

Security Exchange Name

NASDAQ

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=DRMA_WarrantsExercisableForOneShareOfCommonStockMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: